Ergoteles’s ProQR Therapeutics PRQR Stock Holding History

Ergoteles’s Portfolio PRQR Stock Details PRQR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-24,800	Closed	-$104K	–	1002
2020 Q4	$104K	Buy	+24,800	New	+$105K	﹤0.01%	627

Other funds holding PRQR

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Ergoteles's PRQR Position: Q1 2021 in Review

Ergoteles sold out of ProQR Therapeutics (PRQR) in Q1 2021, closing a stake of 24,800 shares — an estimated $104K sold.

Ergoteles first reported a position in PRQR in Q4 2020 and held it in 1 quarter. The position peaked at $104K in Q4 2020. 64 funds tracked by Wall St. Rank hold PRQR as of Q1 2021.

Ergoteles reported no remaining ProQR Therapeutics position as of Q1 2021 after selling out during the quarter.
Ergoteles sold 24,800 ProQR Therapeutics shares in Q1 2021, an estimated $104K.
Ergoteles first reported a position in ProQR Therapeutics in Q4 2020 and held it in 1 quarter.
Ergoteles's ProQR Therapeutics position peaked at $104K in Q4 2020.
64 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q1 2021.

Based on Ergoteles's 13F filing for Q1 2021, filed 12 May 2021.